SPR

Across TCGA pan-cancer cohorts, SPR mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SPR data layer compared with 22 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SPR mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SPR expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where SPR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.935	0.715	<.001	60	view →
CCRCC	DFS	Median	All	0.721	0.890	.030	4	view →
HNSC	OS	Tertile	All	0.765	0.886	.047	2	view →
UCEC	DFS	Tertile	All	0.943	0.786	.031	2	view →
LSCC	DFS	Median	II,III,IV	0.963	0.867	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SPR–PDAC (OS)

Open the PDAC breakdown →